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Conditioning-induced damage of the intestinal tract plays a critical role during the onset of
acute graft-versus-host disease (GVHD). Therapeutic interference with these early events
of GVHD is difficult, and currently used immunosuppressive drugs mainly target donor
T cells. However, not donor T cells but neutrophils reach the sites of tissue injury first, and
therefore could be a potential target for GVHD prevention. A detailed analysis of neu-
trophil fate during acute GVHD and the effect on T cells is difficult because of the short
lifespan of this cell type. By using a novel photoconverter reporter system, we show that
neutrophils that had been photoconverted in the ileum postconditioning later migrated to
mesenteric lymph nodes (mLN). This neutrophil migration was dependent on the intestinal
microflora. In the mLN, neutrophils colocalized with T cells and presented antigen on major
histocompatibility complex (MHC)-II, thereby affecting T cell expansion. Pharmacological
JAK1/JAK2 inhibition reduced neutrophil influx into the mLN and MHC-II expression,
thereby interfering with an early event in acute GVHD pathogenesis. In agreement with this finding, neutrophil
depletion reduced acute GVHD.We conclude that neutrophils are attracted to the ileum, where the intestinal barrier is
disrupted, and then migrate to the mLN, where they participate in alloantigen presentation. JAK1/JAK2-inhibition can
interfere with this process, which provides a potential therapeutic strategy to prevent early events of tissue damage-
related innate immune cell activation and, ultimately, GVHD. (Blood. 2018;131(16):1858-1869)
Introduction
Allogeneic hematopoietic cell transplantation (allo-HCT) is a
well-established treatment of a range of hematological diseases
that cannot be cured by conventional chemotherapy.1 More than 1
million HCTs have been performed globally to date, of which 40%
were allogeneic.2 The most common life-threatening complication
after allo-HCT, and the primary factor limiting its success, is acute
graft-versus-host disease (GVHD). The incidence of GVHD in allo-
HCT remains high, despite immunosuppressive medication.3
Overall, 60% of patients develop grade II to IV acute GVHD, 14%
grade III to IV acute GVHD,4 and 30% to 70% chronic GVHD.5 The
current concept of GVHD development is that antigen-presenting
cells expressing foreign major histocompatibility complex (MHC)
and minor histocompatibility antigens activate donor-derived
T cells3 in both lymphoid organs and target tissue.6 The donor
T cells expand and attack the recipient’s tissues, mainly skin, liver,
and gastrointestinal tract, leading to organ damage and dysfunc-
tion.7 Most therapeutic regimens target the alloreactive T-cell ac-
tivation and expansion, such as calcineurin inhibitors, antimetabolites
(methotrexate and mycophenolate),8 posttransplant cyclophospha-
mide,9 or antithymocyte globulin.10,11 Multiple groups have shown
that in the early phase of GVHD before the expansion of alloreactive
cytotoxic T cells, the irradiation or chemotherapy-based condition-
ing regimen lead to the activation of neutrophils,12-14 monocytes,15
and endothelial cells.16,17
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These events are most likely not affected by the therapeutic
strategies that target primarily T cells. In addition, it is also not
known whether neutrophils ultimately contribute to the activa-
tion of the adaptive donor T-cell immune response against foreign
(recipient) MHC or if local tissue damage is their only contribution to
GVHD. The Janus Kinase (JAK) 1 and 2 inhibitor ruxolitinib has
shown activity in reducing GVHD in the mouse model18 and is
currently under investigation in a phase 3 clinical trial for the
treatment of steroid refractory GVHD (NCT02913482). In neutro-
phils, the JAK1pathway is involved ingranulocyte colony-stimulating-
factor-mediated differentiation of neutrophils,19 suggesting that
neutrophil activation may require an intact JAK1 signaling.
In this study, we show that neutrophils do not homogeneously
infiltrate the intestinal tract early after allo-HCT. Rather, they
form clusters in the terminal ileum while absent from the colon.
The ileum is the most exposed site for bacterial translocation,
where neutrophils are recruited and then traffic into the mesenteric
lymph nodes (mLNs), where they interact with and contribute to the
activation of donor T cells. Antibody-based neutrophil depletion
reduced donor T-cell expansion and acute GVHD severity.
JAK1/JAK2 inhibition by ruxolitinib reduced neutrophil numbers
and MHC-II expression on neutrophils in the mLN. These findings
indicate a novel role for neutrophils in mediating cellular commu-
nication between the damaged ileum and the mLN immediately
after allo-HCT and provide a novel therapeutic option to interfere




C57BL/6 (H-2Kb, CD45.1 or CD45.2), BALB/c (H-2Kd, CD45.2),
and FVB mice were purchased from Charles River Laboratory
(Sulzburg, Germany), Janvier Labs (France), or the local stock of
the animal facility at the University of Freiburg. C57BL/6 back-
ground Ptprca (B6.CD45.11, H-2b, CD45.11) and B6D2F1 (H-2b/d,
CD45.21) were purchased from the Animal Resources Centre
(Perth, WA, Australia), and subsequently were housed in steril-
izedmicroisolator cages and received acidified autoclaved water
(pH 2.5) after transplantation. Ccr22/2 mice were provided by
Marco Prinz (UKL Freiburg), Tnf2/2 mice were provided by the
Max Planck Institute of Immunobiology and Epigenetics (MPI
Freiburg); Alox52/2 mice were also housed at the MPI Freiburg,
and Dendra2 (B6;129S-Gt(ROSA)26Sortm1.1(CAG-COX8A/Dendra2)Dcc/J)
mice20 were housed at the UKLWu¨rzburg. Transgenic mice were
usedonly aftergenotyping.Micewereusedbetween6and14weeks
of age, and only female or male donor/recipient pairs were used.
Animal protocols were approved by the Regierungspra¨sidium
Freiburg, Freiburg, Germany (No: G15-018, G16-018 and G17/063)
or approved by the institutional animal ethics committee (QIMR
Berghofer, Australia).
Bone marrow transplantation model
Bone marrow (BM) transplantation experiments were performed
as described.13 The major mismatch strain combinations used
were C57BL/6 into BALB/c, BALB/c into C57BL/6, FVB into
BALB/c, or C57BL/6 into B6D2F1, as indicated in the respective
experiments. Briefly, recipients were injected IV with 53 106 BM
cells after lethal irradiation with 900 or 1100 cGy, split into 2
equal doses and 4 hours apart. To induce GVHD, CD4 and CD8
T cells were isolated from donor spleens and enriched by
positive selection with theMACS cell separation system (Miltenyi
Biotec, Germany), according to the manufacturer’s instructions.
Anti-CD4 and anti-CD8 MicroBeads were used. CD41/CD81
T-cell purity was at least 90%, as assessed by flow cytometry.
CD41/CD81 T cells were given at a dosage of 0.3 3 106 to
1 3 107 IV on day 0, as indicated in the respective experiments.
B6D2F1 mice (CD45.21) were lethally irradiated by 1100 cGy at
80.7 cGy/min, using a 137Cs source 1 day before transplant.
To induce GVHD, they were injected intravenously with 5 3 106
BM and 2 3 106 CD31 T cells from B6.CD45.11 mice.
Antibiotic treatment
An antibiotic cocktail consisting of vancomycin, metronidazole,
cefoxitin, and gentamicin (final concentrations 1 mg/mL each)
was added to the drinking water for 14 days before total body
irradiation (TBI). Water bottles were changed every 2 to 3 days.
Aztreonam was dissolved in H2O, and mice received a sub-
cutaneous injection of 75mg/kg once daily for 7 days before and
1 day after TBI or H2O as solvent control.
Inhibitor treatment
Inhibitors, suppliers, concentration, diluent reagent, adminis-
tration route, and treatment regimen is listed in supplemental
Table 1, available on the Blood Web site.
Chemotherapeutic conditioning
Doxorubicin was dissolved in H2O and C57BL/6 mice received
20 mg/kg doxorubicin by intraperitoneal injection. Three days
postinjection, mice were sacrificed and the white blood cell
count was analyzed using an animal hematology analyzer (Scil
Vet ABC). Ileum and mLN were processed for flow cytometric
analysis as described earlier.
Quantitative polymerase chain reaction
Bacterial DNA from intestinal segments (0.5 cm long) was iso-
lated after cutting the segments open longitudinally and re-
moving feces by washing in phosphate-buffered saline.
Epithelial layers were removed by washing in cell dissociation
(CD) buffer (Hanks balanced salt solution without Mg21, Ca21,
5 mM EDTA, 10 mM N-2-hydroxyethylpiperazine-N9-2-ethane-
sulfonic acid) at 37°C for 15 minutes. The washing step was
repeated 3 times. Bacterial and genomic DNAwas isolated using
the QIAamp cador Pathogen Mini Kit (Qiagen) according to the
manufacturer’s instructions, using pretreatment T2 for enzymatic
digestion of tissue and pretreatment B1 for difficult-to-lyse
bacteria.
DNA from stool samples for quantitation of the bacterial load
was isolated using the stool QIAamp DNA Stool Mini Kit (Qia-
gen) according to the manufacturer’s instructions.
Quantitative polymerase chain reaction was performed using
the LightCycler 480 SYBR Green I Master Mix (Roche). Universal
16S primers (785F and 907R) were used for standardization of
bacteria per tissue, and glyceraldehyde-3-phosphate dehydro-
genase primers were used to determine levels of mouse ge-
nomic DNA, which was used as a reference (for primer sequences,
see supplemental Table 2).

























































































































































































































Figure 1. Neutrophil granulocytes selectively form clusters in the ileum after TBI. (A-B) Leukocytes were isolated from duodenum, ileum, and colon from untreated C57BL/6
mice, as well as after TBI, and analyzed by flow cytometry. Neutrophils are defined as viable CD451CD11b1Ly6G1 cells. (A) Representative plots of neutrophil numbers from
untreated samples and 48 hours after TBI. (B) Pooled data from 2 separate experiments showing the percentages of CD11b1Ly6G1 cells of all leukocytes (CD451) at different
points after TBI (n5 6-8). (C) C57BL/6 mice underwent allo-HCT (BALB/c into C57BL/6; 53 106 BM1 106 CD41/CD81 T cells). Leukocytes were isolated at different points after
allo-HCT, and the percentages of CD11b1Ly6G1 cells of all leukocytes (CD451) are shown (n5 4). (D) Three-dimensional light sheet fluorescence microscopy of ileum 48 hours
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Intestinal leukocyte isolation
Intestinal leukocytes were isolated as described.21 In brief, 2- to
4-cm intestinal segments were dissected and Peyer’s patches
removed. Segments were opened longitudinally and rinsed in
phosphate-buffered saline to remove feces. Epithelial cells were
separated from the lamina propria using CD buffer (Hanks
balanced salt solution without Mg21, Ca21, 5 mM EDTA, 10 mM
N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid), and the
remaining tissue was digested with digestion buffer (Hanks bal-
anced salt solution with Mg21, Ca21, collagenase D 0.5 mg/mL,
DNAse 0.5 mg/mL, dispase 0.5 U/mL) to obtain single-cell sus-
pensions that were further processed for flow cytometry.
Flow cytometry
Samples were washed in phosphate-buffered saline, and dead
cells were stained using either Aqua LiveDead (Thermo Fisher) or
Zombie NIR fixable dye (Biolegend). Fc receptors were blocked
using anti-CD16/CD32, before staining with appropriate antibody
concentrations for 30 minutes at 4°C. For a list of antibodies used,
see supplemental Table 3. In some cases, cells were fixed in 0.5%
paraformaldehyde. To calculate the absolute numbers of cells, a
defined number of APC fluorescent beads (BD Bioscience) were
added to the sample. Data were acquired within 2 hours after
staining on a BD LSR Fortessa (BD Biosciences), and analysis was
performed using FlowJo software (FlowJo, LLC).
Giemsa-Wright staining
Neutrophils (CD451CD11b1Ly6G1) were sorted on a FACS Aria III
(BD Biosciences) into a 1.5-mL tube and prepared by cytospin at
47g for 5 minutes onto Superfrost Plus slides. Cells were fixed,
permeabilized, and stained for 3minutes inGiemsaWright Solution
(0.8 g Wright, 0.2 g Giemsa in methanol), followed by addition of
an equal volume of phosphate buffer (pH 6.8) for 15 minutes.
Photoconversion of cells located in the
terminal ileum
To selectively photoconvert cells in the terminal ileum of Den-
dra2 mice, the mice were anesthetized using ketamine-xylazine,
and the abdomens surgically opened. The ileum was carefully
mobilized using cotton swabs and a 2-cm segment of the ileum
exposed to 405 nm light (405 nm Silver LED, Prizmatix; 0.5 NA
polymer fiber with 1500 mm core diameter, Prizmatix; F671SMA-
405 collimator, Thorlabs) for 7minutes. This was done bymoving
the light a 0.2- to 0.5-cm distance alongside the ileum while the
other body parts were shielded. For pain medication, the mice
were treated with buprenorphine (0.1 mg/kg) intraperitoneally
initially and at 0.01 mg/mL in the drinking water. Ten to 14 hours
after surgery, mice were sacrificed and organs processed for
fluorescence-activated cell sorter (FACS). Samples obtained
from a sham-operated, nonilluminated mouse served as fluo-
rescence minus 1 control for gating of photoconverted cells.
Statistical analysis
For statistical analysis, an unpaired t test (2-sided) was applied. If
the data did notmeet the criteria for normality, theMann-Whitney
U test was applied unless stated otherwise in the figure
legend. Data are presented as mean and standard error of the
mean (error bars). Differences were considered significant
when the P value was , .05. P values are indicated as follows:
*P , .05; **P , .01; ***P , .001.
All other methods are presented in the supplemental Methods.
Results
Neutrophil granulocytes form individual clusters in
the ileum after TBI
In prior studies, we and others12,13,22 have shown that recipient
neutrophils infiltrate the intestinal tract after allo-HCT. However,
the kinetics, anatomical localization, and responsible recruiting
stimuli were undefined. We compared the duodenum, ileum,
and colon on consecutive days after TBI and allo-HCT. We ob-
served a selective increase of neutrophils in the terminal ileum that
was severalfold higher than that of the duodenum or colon
(Figure 1A-C). Absolute numbers of neutrophils increased in the
ileum after TBI, while decreasing in other organs, including the
spleen (supplemental Figure 1A-B). Infiltration of the ileum by
neutrophils was not different when the mice underwent syn-
geneic or allogeneic HCT (supplemental Figure 1C). However,
in the absence of allogeneic T cells, the mucosal injury exerted
by the neutrophils in the syngeneic setting can heal, whereas in
the allogeneic setting the neutrophil induced tissue damage
promotes activation of allogeneic T cells and, as a secondary
consequence, acute GVHD. Neutrophils accumulating in the
ileum and mLN were mainly (99%) recipient derived (supple-
mental Figure 1D). The peak of neutrophil infiltration into the
ileum was reached at 3 days after TBI and allo-HCT (Figure 1B).
Neutrophils were not evenly distributed but accumulated in
clusters (supplemental Figure 2A-B) that could be visualized by
light sheet fluorescence microscopy and three-dimensional
reconstruction of the ileum wall (Figure 1D; supplemental Video 1).
CD11b1 myeloid cells other than neutrophils did not form
clusters (supplemental Video 2). Closer analysis revealed that
neutrophils selectively accumulated at the bottom of the crypts
(Figure 1E) in close proximity to the lymphatic vessels of the ileum
(supplemental Video 3).
To test for stimuli released early after TBI conditioning, we
analyzed changes in cytokine expression in ileum and colon
24 hours after TBI (supplemental Figure 3A). Although there was
a pronounced change in the ileal cytokine expression profile
(12 cytokines.1.53 upregulated), there were onlyminor changes
in the colon (1 cytokine .1.53 upregulated), indicating that the
ileum is more susceptible to TBI (supplemental Figure 3B). As
expected, the myeloperoxidase that is strongly expressed in
neutrophils was highly upregulated in the ileum. Chemo-
attractants that have been reported to be involved in neutrophil
attraction, including CXCL1, CXCL2, CXCL5, and IL-17A, did
not increase after TBI (supplemental Figure 3C). CD160, a glyco-
protein mainly expressed on intraepithelial lymphocytes,
Figure 1 (continued) after TBI showed cluster formation of neutrophils (Ly6G, red; CD11b, green; tissue autofluorescence, blue). (E) Immunofluorescence staining of ileal cross-
section 48 hours after TBI showed localization of neutrophils adjacent to intestinal crypts (Collagen IV, green; Ly6G, red; scale bar, 50 mm). (F) Bacterial load in lamina propria
of duodenum, ileum, and colon of untreated C57BL/6 mice and C57BL/6 mice 48 hours after TBI was analyzed by quantitative reverse transcription-polymerase chain reaction.
16S rDNA content was normalized to mouse genomic DNA (glyceraldehyde-3-phosphate dehydrogenase). Pooled data from 2 individual experiments are shown (n 5 6).
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Figure 2. Neutrophils migrate from the ileum to the mesenteric lymph node.Mice transgenic for the photoconvertible green-to-red protein Dendra2 in all cells underwent
TBI. After 10 or 34 hours, the ileum was exposed to 405-nm light during surgery to convert Dendra2 from its green to the red fluorescent form. Mice were sacrificed 10-14 hours
after illumination and the amount of photoconverted cells that had trafficked from ileum to spleen, mLN, ndLN (nondraining lymph node, pooled iLN and aLN), blood, and
BM was determined. (A) Illustration of experimental setup. (B) Representative fluorescence image showing successful photoconversion selectively in the ileum after surgery.
(C) Representative FACS plots of photoconverted CD451CD11b1Ly6G1 cells 48 hours after TBI in different organs. Pixel size of dots was increased for better visibility.
(D-E) Percentage of photoconverted CD11b1Ly6G1 neutrophils is shown. (D) Photoconversion on day 0, 10 hours post-TBI, and analysis on day 1, 24 hours post-TBI, according


















IE user on 07 April 2020
showed the highest change in expression in the ileum (sup-
plemental Figure 3B). When analyzing for CD1601 cells by flow
cytometry, we observed high abundance of CD1601 cells in the
epithelial layer, whereas only few cells resided in the lamina
propria. However, CD1601 cells did not increase in numbers
(supplemental Figure 3D) after TBI.
To investigate the role of other stimuli potentially attracting
neutrophils to the ileum wall, we used mice genetically lacking
tumor necrosis factor, CCR2, or 5-Lipoxygenase (Alox52/2) as
recipients. These molecules were chosen on the basis of reports
indicating their roles in neutrophil chemotaxis in other situations
of an innate immune response.23-25 We found unaltered neu-
trophil infiltration into the ileum in the individual absence of any
of these molecules (supplemental Figure 3E), indicating that
individually they are not necessary for neutrophil recruitment to
the ileum during the early phase of GVHD.
By using pharmacological inhibitors, we could also exclude the
involvement of other factors known to play a role in myeloid cell
chemotaxis, including sphingosine-phosphate 1 receptor,
CXCR2, TLR4, and PI3K (supplemental Figure 3F). In addition,
butyrate, which has been shown to be protective for the in-
testinal wall during GVHD,26 had no effect on neutrophil re-
cruitment (supplemental Figure 3F). These findings indicate a
strictly time- and location-dependent influx of neutrophils into
the terminal ileum after allo-HCT, which is independent of
several of the previously described stimuli driving myeloid cell
chemotaxis in other disease models.
We hypothesized that the difference in neutrophil recruitment
reflected differential translocation of bacteria into the intestinal
wall in the various sections of the gut. Therefore, we analyzed the
different intestinal regions with respect to the presence of
bacterial 16S rDNA in the bowel wall. The increase of bacterial
16S rDNA in the ileal wall on TBI was substantial and significant.
In the duodenum and the colon wall, in contrast, there was al-
most no increase in bacterial DNA detectable (Figure 1F),
supporting the concept that the translocation of bacteria is
responsible for the early infiltration of neutrophils specifically
into the ileum after allo-HCT, and that this translocation is
the variable that determines the initiation of GVHD in the
ileum. By sequencing the translocating bacteria in the lamina
propria of the ileum before and after TBI, we observed that
Clostridiales species were enriched, whereas the abundance
of Bdellovibrionales and Desulfovibrio was decreased (sup-
plemental Figure 4A).
Neutrophils migrate from the ileum to the mLN
Dendritic cells (DCs) traffic from the intestinal tract to secondary
lymphoid organs to participate in T-cell activation in GVHD.27 To
understand whether neutrophils that have been activated in
the intestinal tract later migrate to mLN, we used mice transgenic
for the Dendra2 protein,20 a photoconvertable fluorescent protein
that undergoes an irreversible emission shift from green to red
fluorescence on illumination with 405-nm light (Figure 2A).
We observed successful conversion of the Dendra2 protein in
neutrophils when the ileum was selectively illuminated in a
surgical procedure (Figure 2B; supplemental Figure 5A-B). The
ileum was then placed back in the abdominal cavity, and the
abdomen was surgically closed. After 10 to 14 hours, lymphoid
organs were analyzed for the presence of red Dendra2-positive
cells. To better evaluate neutrophil migration kinetics, we ana-
lyzed the frequency of photoconverted neutrophils on day 1 and
day 2 after TBI, in both cases 10 to 14 hours after the ileum had
been exposed to 405-nm light. We detected the highest
frequency of photo-converted ileum-derived neutrophils in
the mLN, which drains the ileum (Figure 2C-E; supplemental
Figure 5C). In contrast to these endogenous neutrophils
recruited via the lymphatic system from the ileum to the mLN,
exogenous BM-derived neutrophils injected intravenously ac-
cumulated mainly in the spleens of the recipients (Figure 2F-G).
A sham-operated, nonilluminated mouse served as fluorescence
minus 1 control for correct gating of photoconverted cells
(supplemental Figure 5C). In addition to neutrophils, CD11c1
DCs also were found to migrate from the ileum to the mLN
(supplemental Figure 5D). These findings provide evidence that
neutrophils migrate from the ileum to the mLN after TBI.
Neutrophils translocate to the mesenteric lymph
nodes mediating cellular communication between
the tissue injury site and the secondary
lymphoid organ
Tissue damage translates into GVHD when alloreactive T cells
are activated by the release of cytokines and enhanced antigen
presentation by antigen-presenting cells. Our data show that
neutrophils migrate from the damaged intestinal tract to the
mLN, where some T-cell priming takes place. We next validated
this finding by analyzing the neutrophil counts in lymphoid or-
gans after irradiation. We detected increased neutrophil num-
bers in the mLN, but not in inguinal (iLN) or axillary (aLN) lymph
nodes or in the spleen (Figure 3A).
Similarly, DCs also infiltrated the mLN (supplemental Figure 6A);
however, the relative increase of neutrophils was higher. mLN-
derived CD451CD11b1Ly6G1 cells, isolated by cell sorting,
showed neutrophil-typical hypersegmented morphology
(Figure 3B). In individual mice, there was a positive correlation
between neutrophil infiltration in the ileum and in the mLN,
which provided additional evidence that neutrophils infiltrating
the ileum moved on to its draining lymph nodes (Figure 3C).
To understand whether bacterial translocation through the ileum
translated into increased appearance of bacterial components in
the mLN, we determined 16S rDNA in that organ. Copies of 16S
rDNA were significantly increased in the mLN at 48 hours after
TBI compared with untreated mice (Figure 3D); this finding was
Figure 2 (continued) to setup A1 (n5 6 for each organ from 2 independent experiments). (E) Photoconversion on day 1, 34 hours post-TBI, and analysis on day 2, 48 hours after
TBI according to setup A2 (n 5 7 for each organ from 2 independent experiments). (F-G) Neutrophils from the BM of mice transgenic for the photoconvertible green-to-red
fluorescence protein Dendra2 were isolated and enriched by MACS purification. The cells were photoconverted ex vivo, and 107 neutrophils were adoptively transferred into
C57BL/6 mice 34 hours after they underwent TBI. Fourteen hours after injection and 48 hours after TBI, mice were sacrificed, and photoconverted Dendra2 cells in spleen, mLN,
ileum, and blood was analyzed by flow cytometry. (F) Representative FACS plots of photoconverted CD451CD11b1Ly6G1 cells derived from the spleen. (G) Percentage of
photoconverted CD11b1Ly6G1 neutrophils in different organs is shown (n 5 8).
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confirmed by sequence analysis (supplemental Figure 6B). We
hypothesized that the influx of bacteria or their constituents into
the mLN would attract neutrophils, which led us to study their
presence under various conditions. The increased infiltration of
the mLN by neutrophils was abrogated when the mice had been
treated with antibiotics before TBI (Figure 3E), underlining the
dependence of neutrophil migration on the presence of bac-













































































































































































Figure 3. Neutrophil infiltration in lymphatic organs. (A) Neutrophil counts in spleen, mLN, iLN, and aLN at different points after TBI were analyzed by flow cytometry. Fold
change of absolute numbers with regard to untreatedmice (day 0) is presented (n5 6 for each point and organ from 2 independent experiments). (B) Giemsa-Wright staining of
mLN-derived CD451CD11b1Ly6G1 neutrophils after FACS sorting and cytospin. (C) Correlation of neutrophil frequency in mLN and ileum from WT or solvent control-treated
mice (n 5 57). (D) Bacterial load in mLN of untreated C57BL/6 and 48 hours after TBI were analyzed by quantitative reverse transcription-polymerase chain reaction. 16S rDNA
content was normalized to genomic DNA (glyceraldehyde-3-phosphate dehydrogenase). (E) Fold change of neutrophil numbers on day 2 after TBI normalized day o d0 (no TBI)
in C57BL/6 mice with and without gut decontamination is shown (Control treatment, n 5 10; gut decontamination, n 5 6 each point and organ from 2-3 independent
experiments). (F) C57BL/6mice were treated daily by subcutaneous injection of aztreonam (75mg/kg/d) or solvent control from day27 until day11 and underwent TBI on day 0.
Fold change of neutrophil numbers on day 2 post TBI normalized to mean of solvent controls is shown (n5 11 pooled from 2 independent experiments). (G) BALB/c mice were
treated daily by subcutaneous injection of aztreonam (75mg/kg/day) or solvent control from day27 until day11 and received allo-HCT (C57BL/6 into BALB/c; 53 106 BM cells1
0.3 3 106 CD41/CD81 T cells) on day 0, and survival was monitored (n 5 20 for each group pooled from 2 independent experiments). (H) C57BL/6 mice received 20 mg/kg
doxorubicin on day 0 or were left untreated. The mLN were analyzed on day 3 by flow cytometry to assess neutrophils counts (CD451CD11b1Ly6G1). Fold change of neutrophil
numbers normalized to the mean of untreated samples is shown (n 5 10 for each group pooled from 2 independent experiments).
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feces by 45 000 times (supplemental Figure 6C), which is dif-
ferent from the broad-spectrum antibiotics given to patients
after allo-HCT that do not aim at completely eliminating all
bacteria. Treatment with aztreonam reduced neutrophil re-
cruitment to the ileum (supplemental Figure 6D) and mLN
(Figure 3F) and GVHD-related death compared with the vehicle
control group (Figure 3G). In addition, we analyzed the effect of
doxorubicin on neutrophil recruitment to the intestinal tract. We
observed that at day 3 postdoxorubicin administration, when the
white blood count in the peripheral blood was decreased
(supplemental Figure 6E), the frequency of neutrophils was still
increased in the ileum (supplemental Figure 6F) and the mLN
(Figure 3H) compared with untreated mice.
Neutrophils in the mesenteric lymph node and
ileum express high levels of MHC-II and contribute
to the expansion of donor T cells
To better understand whether the neutrophils that had migrated
from the ileum to the mLN in a bacteria-dependent manner
would interact with donor-derived T cells, we analyzed inter-
actions of neutrophils and T cells in the mLN. We observed an
accumulation of neutrophils around the T-cell zone in close
proximity to lymphatic vessels (Figure 4A) and a frequent co-
localization of neutrophils with donor type (CD45.11) T cells
(Figure 4B).
Neutrophils are not considered classical antigen-presenting
cells. However, several reports have indicated that activated
neutrophils can express MHC II and can indeed effectively
present antigen to T cells.28 We hypothesized that such in-
teraction between neutrophils and T cells may take place after
TBI and next determined the MHC-II levels of neutrophils
derived from spleen, mLN, iLN, aLN, or ileum, after irradiation.
We found a significantly greater proportion of MHC-II ex-
pressing neutrophils in the ileum and mLN compared with
neutrophils residing in nondraining lymph nodes or the spleen
(Figure 4C-D).
To determine whether neutrophils can present host antigens in a
recipient MHC-II-dependent manner and whether they increase
their presentation capacity after TBI, we used a previously de-
scribed system using the YAe antibody. This antibody stains the
complex of Ea peptide (I-Ad derived from DBA/2) bound to I-Ab
(expressed on C57BL/6).29 Recipient mice (B6D2F1) were the
F1 generation of C57BL/6 and DBA/2 mice, and therefore
expressed DBA/2 MHC-II (I-Ad). We observed that a proportion
of neutrophils was indeed presenting Ea peptide in the context
of MHC-II (Figure 4E). Both the percentage and the absolute
numbers of YAe1/MHC-II1 neutrophils present in the mLN in-
creased by 48 hours after BM transplantation compared with
untreated mice (Figure 4F), indicating the enhanced ability of
these neutrophils to participate in antigen presentation to donor
T cells. Indeed, depletion of neutrophils with anti-Ly6G anti-
bodies caused a small but statistically significant reduction in
CD4 T-cell proliferation in the mLN (Figure 4G-H). Decreased
T-cell expansion in mice treated with anti-Ly6G antibody was not
a result of decreased MHC-II or CD80/86 expression on DCs, as
these markers were even increased on DCs after anti-Ly6G Ab
treatment (supplemental Figure 7A-B). Anti-Ly6G antibody
treatment reduced GVHD-related death at 2 different T-cell
dosages (Figure 4I; supplemental Figure 7C).
Ruxolitinib treatment reduces numbers of
neutrophils in the mLN as well as their
MHC-II expression
Small-molecule kinase inhibitors have shown great potential for
the therapeutic interference with signaling pathways in both
cancer and immune cells. Ruxolitinib is a JAK1/JAK2 inhibitor
that can reduce GVHD in preclinical models. To test whether
JAK1/JAK2 are involved in neutrophil migration and activation
during GVHD, we treated mice with the ruxolitinib twice daily
and analyzed neutrophil numbers in ileum and mLN, together
with MHC-II and CD80/CD86 levels on these cells. Mice treated
with ruxolitinib had lower absolute numbers of leukocytes and of
neutrophils in the mLN, whereas no significant changes were
observed in the ileum (supplemental Figure 8A; Figure 5A).
Although CD80/86 expression remained unchanged (supple-
mental Figure 8B), the frequency of MHC-II1 neutrophils 48 hours
after TBI in the ileum and mLN was reduced in ruxolitinib-treated
mice compared with control irradiated mice (Figure 5B-C). In
addition, the neutrophils that did migrate to the mLN in
ruxolitinib-treated mice showed lower MHC-II expression com-
pared with vehicle-treated mice (Figure 5D-E).
The numbers of MHC-II1 neutrophils in the mLN were positively
correlated with the numbers of MHC-II1 neutrophils in the ileum
in mice undergoing TBI and vehicle treatment (Figure 5F). This
correlation was not seen when mice had been treated with
ruxolitinib (Figure 5F). This indicates that despite infiltration of
the ileum, neutrophil trafficking from the ileum to mLN is dis-
rupted by treatment with ruxolitinib. In summary, these results
show that ruxolitinib treatment can reduce neutrophil numbers
in the mLN and inhibit their ability to stimulate T cells in the mLN
resulting from lower MHC-II expression.
Discussion
Early events of GVHD include the release of damage-associated
molecular patterns30-32 and the activation of Ag-presenting cells
that later prime donor T cells. A recent study has shown that
when GVHD is established, donor CD1031 DCs that were
stimulated by damage-associated molecular patterns/pathogen-
associated molecular patterns then migrate from the colon to the
mLN and provide a feed-forward loop to amplify GVHD.27 In
the study presented here, we analyzed events that precede
established GVHD and found that after TBI, the terminal ileum is
the most vulnerable site to intestinal leakage, leading to the most
abundant infiltration by neutrophils. Although the ileum is far less
densely colonized by bacteria than the colon, both bacterial rDNA
and bacteria-dependent neutrophil infiltration were much
more pronounced in the ileum wall compared with the colon. By
using a photoconverter in vivo system, we could show that
neutrophils that had been converted in the ileum later appeared in
the mLN. Colocalization of neutrophils and donor T cells in the
mLNwas observed, and functional studies revealed reduced CD4
T-cell expansion when neutrophils were reduced by antibody-
mediated depletion. In addition to direct T-cell priming, it is likely
that neutrophils affect T-cell expansion indirectly via increased
inflammation resulting from tissue damage in the ileum.
Translocated bacteria are essential for the neutrophil migration.
When using antibiotics-based decontamination before TBI, we
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found no trafficking to the mLN. Depletion of neutrophils
resulted in reduced CD4 T-cell proliferation and reduced GVHD
severity. These observations indicate that both phenomena,
translocated bacteria and intestinal neutrophil accumulation, are
connected and play a role in GVHD. Although neutrophils are
classically thought to express low cell-surface levels of MHC-II,
we observed high levels for mLN or ileum-derived neutrophils
after TBI. Consistent with these findings, neutrophils have been
found to be able to prime T cells in vitro,28 in a colitis model,33,34
and in a skin injury model.35 These reports are in agreement with
our observation that neutrophils in the mLNmigrated there from
the ileum and presented recipient antigen to donor T cells. Our
finding that neutrophil depletion reduces GVHD-related death
indicates a role of neutrophils in GVHD. However, how pivotal
the role is under different clinical conditions, such as reduced
intensity conditioning, has still to be determined.
Beyond the novel biological observation that neutrophils con-
tribute to T-cell priming, we also provide evidence of the po-
tential usefulness of a therapeutic intervention that may allow
countering early innate immune activation after tissue damage.
We observed that the JAK1/JAK2 inhibitor ruxolitinib reduced
the stimulatory capacity of neutrophils by reducing their MHC-II











































































































































































Figure 5. JAK1/JAK2 inhibition reduces neutrophils andMHC-II expression.C57BL/6 mice were treated twice daily with 30 mg/kg ruxolitinib starting on day21 before TBI.
On day 2 after TBI, mice were sacrificed and analyzed by flow cytometry. (A) Absolute numbers of neutrophils (CD451CD11b1Ly6G1) in mLN and ileum. (B) Representative
histogram of MHC-II expression on CD451CD11b1Ly6G1 neutrophils in ileum after ruxolitinib or solvent control treatment. (C) Frequency of MHC-II1 (% of CD451CD11b1Ly6G1)
neutrophils in ileum and mLN after ruxolitinib or solvent control treatment. (D) Fold change of MFI for MHC-II on MHC-II1CD11b1Ly6G1 cells isolated from mLN or ileum. (E) Fold
change in absoluteMHC-II1CD451CD11b1Ly6G1numbers by ruxolitinib treatment normalized to solvent control. (F) Correlation ofMHC-II1CD451CD11b1Ly6G1neutrophil numbers
in mLN vs ileum after ruxolitinib or solvent control treatment.
Figure 4. Antigen presentation by neutrophils. (A) Immunofluorescence staining of a mLN 48 hours after TBI showing ring-shaped localization of Ly6G1 cells (red) around
lymphocytes next to lymphatic vessels (Lyve-1, green; 49,6-diamidino-2-phenylindole, blue; blood vessels (CD31), white; scale bar, 200 mm). (B) MLN 48 hours after allo-HSCT
showing neutrophils (Ly6G1 5 red) close to transplanted CD45.11 T cells (green, scale bar5 150 mm). (C) Representative histogram of MHC-II expressing CD451CD11b1Ly6G1
neutrophils in spleen, iLN, aLN, mLN, and ileum in C57BL/6 mice 48 hours after TBI. (D) Frequency of MHC-II1 (percentage of CD451CD11b1Ly6G1) neutrophils in different
organs in CD57Bl/6 mice 48 hours after TBI. (E-F) MHC-II expression and peptide presentation (YAe1) on CD11b1Ly6G1 neutrophils in B6D2F1 mice were assessed by flow
cytometry in untreated mice, 24 hours after TBI and 48 hours after BM transplantation. (E) Representative FACS plots showing gating strategy. (F, left) Relative numbers of
YAe1MHC-II1 cells of host neutrophils. (Right) Absolute numbers of host YAe1MHC-II1 neutrophils. (G-H) For neutrophil depletion, BALB/c mice were injected with either
anti-Ly6G (0.5mg intraperitoneally) or an isotype control (0.5mg) on day21 and transplanted after TBI on day 0 with 13 107 purified and CellTrace Violet-labeled CD41/CD81 T cells
from C57BL/6 mice. Mice were sacrificed on day 3 and mLN analyzed for donor-derived (H2kb1) T cells that had proliferated. (G) Representative flow cytometry plots of CellTrace
Violet-dilution ofH2kb1CD41T cells. (H) Pooled data from 2 independent experiments showing proliferatedH2kb1CD41T cells after anti-Ly6Gneutrophils depletion. (I) BALB/cmice
were treated on day 21 by anti-Ly6G (0.5 mg) or isotype control antibody (0.5 mg) injection and underwent allo-HCT (FVB into BALB/c; 5 3 106 BM cells 1 0.5 3 106 CD41/CD81
T cells). BM controls were treated on day 0 by isotype control antibody (0.5 mg) injection and underwent transplantation using BM alone (FVB 5 3 106 cells).
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number of neutrophils in the mLN. Intriguingly, neutrophils were
still able to migrate to the ileum but were prevented from
moving on to the mLN. It is clear that DCs play an important role
in the stimulation of T cells in GVHD, and our data presented
here suggest that neutrophils also play a role in direct T-cell
activation, and that ruxolitinib also affects the T-cell-stimulating
function of neutrophils. These findings are consistent with our
previous findings showing that the JAK/STAT/MHC-II axis in
DCs can be blocked by ruxolitinib.36 Thus, ruxolitinib acts on both
types of APCs, and thereby interferes with major events of early
GVHD. A next step could be to bring early JAK1/JAK2 inhibition
in the clinic as a prophylactic, rather than only therapeutic,
strategy. By reducing the contribution of neutrophils to early
events in GVHD pathophysiology, one could potentially improve
the outcome of patients undergoing allo-HCT.
In summary, we provide a characterization of the patho-
mechanistic chain of bacterial transmigration into the ileum wall,
subsequent neutrophil recruitment, neutrophil migration into
the draining lymph node, presentation of host-derived antigen
by neutrophils, and consecutively increased donor T-cell ex-
pansion. Our findings improve our understanding of the early
pathogenic steps of GVHD and identify a contribution of neu-
trophils to the adaptive allogeneic immune response. In addi-
tion, we were able to interfere therapeutically with the process
by JAK1/JAK2 inhibition through ruxolitinib, reducing the ac-
cumulation of neutrophils and DCs in the mLN, as well as re-
ducing MHC-II expression of these cell types. This offers a
rational explanation of the use of kinase inhibitors as a potential
therapeutic option, to inhibit antigen-presentation after condi-
tioning induced tissue damage, an early step in the initiation
of GVHD.
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